<DOC>
	<DOCNO>NCT00119756</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability intramuscular injection ( buttock shoulder ) paliperidone palmitate patient schizophrenia .</brief_summary>
	<brief_title>A Safety Tolerability Study Paliperidone Palmitate Injected Shoulder Buttock Muscle Patients With Schizophrenia</brief_title>
	<detailed_description>To date , prior trial involve intramuscular injection paliperidone palmitate conduct buttock administration . This randomized , multicenter , crossover design study evaluate safety tolerability paliperidone palmitate two different injection site . The study hypothesis difference safety tolerability buttock injection compare shoulder injection three different dos paliperidone palmitate . The patient receive intramuscular injection paliperidone palmitate either buttock shoulder</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Paliperidone Palmitate</mesh_term>
	<criteria>The patient must sign informed consent The patient must meet diagnostic criterion schizophrenia Female patient must postmenopausal least 2 year negative pregnancy test result screen The patient must able perform study requirement ( e.g . answer questionnaire ) Primary , active diagnosis schizophrenia Psychiatric inpatient hospitalization relapse symptom schizophrenia past 90 day Change antipsychotic medication past 45 day Diagnosis active substance dependence within 3 month History treatment resistance History concurrent significant unstable disease ( e.g . heart , lung , liver disease )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Intramuscular injection</keyword>
	<keyword>Deltoid muscle</keyword>
	<keyword>Gluteus muscle</keyword>
	<keyword>Paliperidone palmitate</keyword>
</DOC>